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Abstract. Follicular lymphoma (FL) is the second most common histotype of non-Hodgkin’s 
lymphoma, and it is generally characterized by a heterogeneous clinical course. Despite recent 
therapeutic and diagnostic improvements, a significant fraction of FL patients still relapsed. In 
younger and/or fit FL relapsed patients bone marrow transplant (BMT) has represented the 
main salvage therapy for many years. Thanks to the ability of high-dose chemotherapy to 
overcome the lymphoma resistance and refractoriness, autologous stem cell transplantation 
(ASCT) can achieve a high complete remission rate (CR) and favorable outcome regarding 
progression-free survival (PFS) and overall survival (OS). Allogeneic stem cell transplantation 
(alloSCT) combines the high dose chemotherapy effect together with the immune reaction of the 
donor immune system against lymphoma, the so-called ‘graft versus lymphoma’ (GVL) effect. 
Considering the generally higher transplant-related mortality (TRM), alloSCT is mostly 
indicated for FL relapsed after ASCT. During the last years, there have been a great spread of 
novel effective and feasible drugs Although these and future novel drugs will probably change 
our current approach to FL, the OS post-BMT (ASCT and alloSCT) has never been reproduced 
by any novel combination. In this scenario, it is important to correctly evaluate the disease 
status, the relapse risk and the comorbidity profile of the relapsed FL patients in order to 
provide the best salvage therapy and eventually transplant consolidation. 
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Introduction. Follicular lymphoma (FL) is the 
second most common histotype of non-Hodgkin’s 
lymphoma with an incidence of approximately 
15.000 new cases/year in the United States.
1
 The 
incidence increases with age, with the median age 
at diagnosis being 60 years. FL clinical course is 
generally heterogeneous with progression-free 
survival (PFS) ranging from 71% to 35% at 10 
years, according to the Follicular Lymphoma 
Prognostic Index Score (FLIPI),
2
 and 91% to 51 % 
at 3-year, according to with Follicular Lymphoma 
Prognostic Index Score-2 (FLIPI-2).
3
 During the 
last years, the FL clinical management has been 
progressively improved thanks to the use of more 
accurate and sensible diagnostic technics such as 
the Positron Emission Tomography (PET) and the 
Minimal Residual Disease (MRD) monitoring
4-11
 
and the introduction of novel effective agents.
12
 
Anti-CD20 humanized antibody Rituximab led to 
one of the most important changing in FL clinical 
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practice, and probably still represents the major 
improvement in FL therapy and outcome in the 
last 20 years.
13-15
 Indeed, different studies show 
how the combination of rituximab and standard 
chemotherapy (i.e, CHOP) can significantly 
improve the FL prognosis and survival compared 
to standard chemotherapy alone. Despite all these 
advances, a significant proportion of FL patients 
still experiences an early or late relapse. 
Bone marrow transplant (BMT) has been 
widely investigated to achieve a better response 
and improve the survival in FL.
16-18
 Autologous 
stem cell transplantation (ASCT) has represented 
one of the main treatment for relapsed FL thanks 
to the ability of high-dose chemotherapy to 
overcome the lymphoma resistance and 
refractoriness. Allogeneic stem cell transplantation 
(alloSCT) combines the high dose chemotherapy 
effect together with the immune reaction of the 
donor immune system against lymphoma, the so-
called ‘graft versus lymphoma’ (GVL) effect. 
Although the BMT anti-lymphoma activity is 
generally superior to standard chemotherapy, this 
approach is limited to young and fit patients due to 
the transplant-related toxicity and mortality 
(TRM). In the last years, thanks to the novel less 
toxic conditioning regimens available and to the 
significant improvement in supportive cares, the 
proportion of FL patients potentially eligible to 
ASCT and/or alloSCT has progressively 
expanded. Today these procedures are feasible up 
till the age of 65-70 years.
16, 17
  
In this review we examine the current state of 
the art of FL treatment, focusing in particular on 
the role of BMT and its indications. 
 
Transplant in the First Line: End of the Story? 
In the pre-rituximab era, three different main trials 
investigated the role of intense chemotherapy with 
final ASCT consolidation as first-line therapy for 
FL patients.
19-21
 Although this approach showed a 
significant progression-free survival (PFS) 
improvement, the advantage was abolished by the 
high incidence of therapy-related malignancies 
seen in the ASCT arms.
22-24
 The Gruppo Italiano 
Trapianto di Midollo Osseo (GITMO) investigated 
the combination of rituximab with high-dose 
sequential (HDS) chemotherapy regimens, 
including ASCT as final consolidation, showing a 
significant improvement in terms of PFS and 
overall survival (OS).
25
 However, the first 
randomized trial conducted by GITMO and 
Intergruppo Italiano Linfomi (IIL) failed to 
demonstrated any survival advantage of R-CHOP 
followed by ASCT compared to R-CHOP alone in 
high-risk FL patients.
7
 Enrolling a total of 136, 
patients this study represents the main clinical trial 
that investigated the role of ASCT in the first line 
FL in rituximab era. After a median follow-up of 
51 months, the ASCT arm showed a clear 4-year 
event-free survival (EFS) advantage (62% versus 
28%); however, no difference was seen in OS 
(81% versus 80%), confirming what was 
previously described in trials without the anti-
CD20 monoclonal antibody. The final results of 
this trial were particularly interesting considering 
the MRD monitoring data. A significantly higher 
rate of molecular remissions (MRs) was achieved 
in the ASCT arm compared with the conventional 
chemotherapy (80% versus 44%, respectively), 
with MRD status being the strongest predictor of 
outcome. Importantly, patients randomized to the 
non-transplant arm that achieved MRD negativity 
did not show any difference in outcome compared 
to MRD-negative patients who underwent ASCT.
7
 
These data suggest that MRD negativity should be 
considered as one of the main end points in FL 
therapy. 
A further improvement in PFS post R-CHOP 
was recently obtained by the introduction of 
rituximab maintenance, as demonstrated by the 
PRIMA trial.
26
 The last update showed a PFS at 6-
year of 59% in maintenance vs. 42.7% of the non-
maintenance arm.
27
 These results demonstrate that 
standard immune-chemotherapy regimens may 
achieve a long remission in more than half FL 
patients. A sub-analysis of the PRIMA study also 
showed that PET-positive patients had a 
significantly inferior PFS at 42 months compared 
to those who became PET negative (32.9 versus 
70.7%). The risk of death was also increased in 
PET-positive patients.
28
 In this perspective, the 
introduction of the PET scan into the clinical 
practice may further improve the disease response 
evaluation, because it may be able to detect 
patients with refractory disease or with an early 
complete remission.
5,9-11,29
 An ongoing 
prospective trial of the Fondazione Italiana 
Linfomi (FIL) group is evaluating whether the 
disease assessment by combination of MRD 
monitoring and PET scan after rituximab-based 
induction therapy can identify FL patients who 
need an intensification or, conversely, those that 
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may avoid rituximab maintenance therapy 
(EUDRACT NUMBER: 2012-003170-60). 
Finally, the incorporation of novel agents such 
as bendamustine and lenalidomide in the first line 
treatment showed promising results that may 
produce further potential improvement in term of 
efficacy and toxicity among all FL.
30-34
 
In conclusion, considering the absence of 
survival benefit of ASCT consolidation and the 
continuous improvements in non-transplant 
approaches, ASCT should be avoided in the first 
line therapy for FL patients. 
 
Relapsed Follicular Lymphoma Patients: New 
Drugs vs. High Dose Chemotherapy. Although 
the significant therapeutic advances achieved over 
the last years, approximately 40% of all FL 
patients relapse in a different way and at different 
time after the first line.
12, 18
 A recent study showed 
a dismal clinical outcome among FL patients 
relapsed in the first year after R-CHOP with a 5-
year OS rate of 34% (95% CI, 19% to 60%), 
confirming the early relapse as an indirect 
parameter of refractoriness and poor outcome.
35
 
Based on these data, it is crucial to provide the 
best salvage therapy for these high-risk and early 
relapsed FL patients. Conversely, the FL patients 
who relapse after more than two years are 
associated with a very favorable survival with a 5-
year OS of 94%,
12,35,36
 and the indication for 
ASCT as salvage treatment in this subgroup is not 
clear.
37
 In fact, the treatment choice (ASCT versus 
other less intensive regimens) should always be 
based on patient symptoms, disease burden such as 
the presence of bulky disease and/or extranodal 
involvement, and/or signs of rapidly progressive 
lymphoma. For patients relapsed after 2 years, 
intense salvage therapies including ASCT are 
usually delayed. In case, localized relapse may be 
managed by the radiotherapy alone and/or 
monoclonal antibodies postponing more intense 
approaches. For this purpose, a careful staging is 
mandatory in all relapsed FL. Figure 1 
summarizes our current approach to FL in first 
relapse after immunochemotherapy. 
 
 
Figure 1. Follicular Lymphoma in First Relapse. 
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Table 1. Select outcomes of ASCT for relapsed or refractory FL.  
 
Number of 
Patients 
R included in 
salvage CT 
PFS OS Ref 
Schouten et al, 2000  65 0 55-58% at 2 year 71-77% at 4 year 24 
Rohatiner et al, 2007 121 0 55% at 5 year 71% at 5 years 44 
Sebban, et al, 2008 98 33% 51% at 5 year 70% at 5 year 45 
Vose, et al, 2008 248 Few (not reported) 44% at 5 year 63% at 5 year 46 
Tarella et al, 2008 61
+ 100% 57 at 5 year 75% at 5 year 25 
Le Gouill et al, 2011 112* 100% 52 at 3 year 92% at 3 year 43 
Le Gouill et al, 2011 53* 0 40 at 3 year 63% at 3 year 43 
Evens et al, 2013 135 100% 57% at 3 year 87% at 3 year 83 
Pettengell et al, 2013 280 0 48-42% at 10 years 66.1-74.5% at 10 year 50 
Klyuchnikov et al#, 2015 250 100% 41% at 5 year 74% at 5 year 41 
Klyuchnikov et al$, 2015 136 100% 36% at 5 year 59 at 5 year 42 
+ considered only R-HDS arm, *Considering the trial end point, bot arm (with and without rituximab) are listed, #Only Grade 2 FL were 
included in this study, $Only Grade 3 FL were included in this study. 
 
FL can transform into an aggressive lymphoma 
at different times.
38
 For this reason, all early 
relapsed FL and/or those with rapidly growing 
nodes, elevated LDH and/or significant extra-
nodal involvement, should be investigated to rule 
out a potential transformation in diffuse large B-
cell lymphoma (DLBCL). In this relapsed setting, 
the differential diagnosis is mandatory, because 
the biological and clinical behavior of transformed 
FL is similar to the one of the DLBCL, thus 
requiring intensive chemotherapy and ASCT.
39
 
Before starting any treatment, an important 
element to consider other than histologic 
transformation is the patient comorbidity status. In 
fact, intense salvage schemes and ASCT 
consolidation should be avoided in old (≥ 65-70 
years) and/or frail patients, considering the risk of 
significant toxicity and complications. 
Nevertheless, the definition of elderly or frail is 
not unique, as addressed in the last paragraph of 
this review. 
In the case of young and fit early relapsed FL 
patients, high dose chemotherapy approaches plus 
ASCT consolidation showed the best results in 
terms of OS and PFS (Table 1).
24,25,40-46
 This 
outcome was further improved by adding 
rituximab into intense salvage regimens. A 
GITMO retrospective analysis reported a 5-year 
EFS and OS of 65% and 80%, respectively, among 
refractory and early relapsed FL treated with 
Rituximab in combination with high-dose 
sequential therapy (R-HDS).
25
 Similar results were 
achieved in late relapsed FL cases with a 5-year 
EFS and OS of 71% and 83%. Overall these data 
showed a significant improvement compared to 
the HDS regimens without rituximab (5-year EFS 
and OS of 23% and 41%, respectively among 
early relapsed and 33% and 65% respectively 
among late relapsed FL patients). In this 
retrospective study authors also included 
rituximab naïve relapsed FL patients, and this may 
partially explain excellent results. Nevertheless, in 
a subanalysis including together all DLBCL and 
FL previously treated with rituximab, the 5-year 
EFS, and OS were 44% and 56%, respectively. 
Considering previously published studies (Table 
1) including relapsed FL patients, the 5-year PFS 
after high dose regimens and ASCT consolidation 
is approximately 40-50%. Furthermore, it is well 
known that the addition of anti-CD20 monoclonal 
antibodies is able to improve the MRD-negative 
peripheral stem cell harvests and, consequently, 
the survival and the rate of MRs after  
ASCT.
7,8,47-50
 
In the last 10 years, different alternative less 
toxic approaches were tested among 
relapsed/refractory FL. Bendamustine represents 
one of the most important agent with a reported 
overall response rate (ORR) of 81% and a median 
PFS of approximately 8 months as a single agent 
in relapsed FL patients.
51
 Interestingly, the 
combination of Rituximab plus Bendamustine in 
the first line did not show any inferiority compared 
to R-CHOP, confirming the high efficacy of this 
agent and its strong synergistic activity with 
rituximab.
30,32,33,51-54
 Fludarabine-containing 
regimens still remain a valid option, although their 
use should be carefully evaluated considering the 
high rate of early and late toxic adverse events.
55
 
An effective agent in relapsed FL is represented by 
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Table 2. Novel published agents in FL in the last years.  
New Agent Classification Reference Cases ORR CR PFS/TTP$ 
Ibritumomab Tiuxetan Radio-conjugated MoAb& Witzig et al. 200256 54 74% 15% Median 6.8moths 
Ofatumumab MoAb anti-CD20 Czuczman, et al, 201263 116 10-13% 0% Median 5.8 moths 
Ibrutinib BTK inhibitor Advani et al. 201258 16 37% 18.5% Median 13.6 months* 
Obinotuzumab MoAb anti-CD20 Sehn et al. 201465 74 44.6% 12.2% 45.8% at 2 year 
Idelalisb# PI3Kδ inhibitor Gopal et al, 201460 72 57% 6% Median 11 months 
R-Pidilizumab anti-PD MoAb Westin et al. 201462 32 66% 52% Median 18.8 months 
Lenalidomide Immunomodulatory Leonard et al, 201561 45 53.3% 20% 27% at 2 year 
R-Lenalidomide Immunomodulatory Leonard et al, 201561 46 76.1% 39.1% 52% at 2 year 
Polatuzumab+ 
Anti-CD79b drug 
conjugate MoAb 
Palanca-Wessels et al, 201566 16 43% 18.5% Median 7.9 moths 
$ PFS= progression free survival/ TTP = time to progression, & MoAb = monoclonal antibody, *considering all lymphomas enrolled in the 
study, # indolent lymphoma of whom 58% FL, +data related to indolent lymphoma study arm. 
 
radio-immunotherapy (i.e., Zevalin®) that should 
be considered preferentially in non-bulky relapse 
with a bone marrow infiltration <20%.
56,57
  
Most recently, several novel molecules have 
shown an interesting activity in relapsed/refractory 
FL patients (Table 2).
12
 Particularly, lenalidomide, 
pidilizumab, and idelalisib demonstrated a strong 
activity and an acceptable toxic profile also when 
combined with rituximab.
58-62
 In addition, few 
novel and potentially more active anti-CD20 
monoclonal antibodies (GA-101 and 
Ofatumumab) are currently under  
investigation,
63-65
 as well as novel conjugated 
monoclonal antibodies (i.e., Polatuzumab).
66
 
Overall, these new molecules are progressively 
bringing significant changes in relapsed FL 
management, and they may improve the outcome 
in the next future. A challenging issue is how to 
integrate these drugs into the therapeutic strategy 
and how to combine them with chemotherapy. In 
fact, although these molecules are not defined as 
“conventional chemotherapy”, they may be 
responsible for very important and unknown 
toxicities. As a matter of fact, two different trials 
testing the combination of novel agents [Pi3K 
inhibitor (Idelalisib) + Immunomodulatory agent 
(Lenalidomide) and Pi3K inhibitor (Idelalisib) + 
Syk Inhibitor (Entospletinib)] were recently 
interrupted for unacceptable toxicity and adverse 
event incidence.
67,68
 In the future, it is conceivable 
that new non-chemotherapic drugs will change the 
salvage therapy paradigm in FL completely. 
However, although a significant fraction of 
relapsed and heavily pretreated FL patients 
achieved disease reduction when treated with these 
novel agents, the median PFS has never reached in 
most of the experiences the survival reported in 
ASCT studies, so far (Table 1-2). Moreover, 
ASCT is well known to induce long-term 
remission in approximately 40-50% of patients. 
For these reasons, we believe that ASCT still 
represents the current standard of care of young 
and fit FL patients in first and early relapse. 
 
 
Conditioning Regimens for Autologous Stem 
Cell Transplantation. The conditioning regimen 
represents one of the most important therapeutic 
factors to obtain the best response after ASCT. 
The most used conditioning regimens are based on 
high dose chemotherapy, TBI–containing regimen 
and more recently the combination of 
chemotherapy and radio-immunotherapy. 
Although there are not any significant data for a 
specific conditioning regimen, the use of total-
body irradiation (TBI) is associated with a higher 
risk of secondary malignancy after transplant 
compared to the chemotherapy-based conditioning 
regimen.
22,23
 Specifically, in the setting of ASCT, 
the relative risk of therapy-related 
myelodysplasias or leukemia development was 
four times more in the TBI-containing group 
compared to others.
23
 For this reason, this 
approach has been progressively abandoned. 
Conversely, radio-immunotherapy, and in 
particular 90Y-ibritumomab tiuxetan (Zevalin®) 
represents a valid option not only for the peculiar 
efficacy that exploits the radiosensitivity of 
lymphoma cells but also for its safety and 
acceptable toxic profile.
56,57,69
 This agent was 
included in myeloablative conditioning to increase 
the anti-lymphoma activity of ASCT, in particular 
in high tumor burden and/or refractory patients at 
the time of transplant.
70,71
 Although the early 
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results are promising, it is not clear what is the real 
advantage of this combination. 
In order to extend the number of patients 
eligible to ASCT, considering the frequent old age 
of FL patients, differently less toxic conditioning 
regimens have been explored in the last years. 
High dose 90Y-ibritumomab tiuxetan (0.8-1.2 
mCi/kg) consolidation after five high dose 
chemotherapy courses showed promising results 
among frail and/or elderly series of relapsed and 
naïve B-lymphomas patients.
72,73
 Although the 
early toxicity profile and the outcome was 
excellent; the updated results showed an 8-year 
cumulative incidence of the secondary 
myelodysplastic syndrome of 9.4%, suggesting an 
increased risk compared with what was previously 
reported among younger patients receiving high-
dose therapy and autograft. On the other hand, a 
high incidence of myeloid cancers was not clearly 
observed when Zevalin® was administered at the 
standard dose.  
Despite the high efficacy of ASCT salvage 
programs in FL, a significant fraction of patients 
still relapse. To further improve the efficacy of 
ASCT, different post-transplant therapeutic 
approaches have been explored. Rituximab post-
transplant maintenance is probably the most 
important one.
36,47,48,74,75
 However, conversely to 
what reported in the first line, there is no sufficient 
evidence supporting the use of rituximab 
maintenance in all FL patients achieving a 
response after autologous ASCT. A potential 
setting may be represented by FL patients that do 
not achieve MRD negativity after transplant. In a 
small report, it was shown that the percentage of 
MRs might be increased by a short rituximab 
consolidation. Further prospective validations are 
needed to confirm these data.
36,47,48,74,75
 
 
Allogeneic Stem Cell Transplantation. AlloSCT 
represents an effective treatment for relapsed and 
refractory FL with 5-years OS ranging from 50-
80%.
16
 Historical studies that compared PFS 
curves of patients who received ASCT or alloSCT 
reported a statistically significant advantage for 
allografted patients. However, the lower relapse 
risk with alloSCT was offset by the higher TRM 
compared with ASCT, leading to similar 5-year 
OS rates of 51%-62%.
76-78
 For this reason, the best 
choice in first relapse patients is still represented 
by ASCT (Figure 1), as previously mentioned. 
Taking into account that about 30-50% of 
autografted patients relapse afterward, alloSCT 
represents an effective salvage strategy that should 
always be considered in these patients. 
Retrospective data on myeloablative alloSCT in 
FL showed a high and quite unacceptable toxicity 
and TRM incidence.
76-78
 For this reason, in the 
past, alloSCT was generally avoided in the 
majority of relapsed/refractory FL patients that 
were usually excluded from myeloablative 
transplant programs due to the age older than 50-
55 years. In order to extend the fraction of eligible 
FL patients and to reduce the TRM, different less 
toxic and more feasible conditioning regimens and 
transplant strategies have been explored. In the last 
twenty years, the most important change in 
transplant approach has been represented by the 
introduction of reduced intensity conditioning 
(RIC) regimens which are associated with a 
reduced TRM without a loss of efficacy provided 
by the GVL effect.
16,17,79
 Thanks to these qualities, 
RIC alloSCT extended the application of 
allotransplant to a larger rate of FL patients that 
were historically considered ineligible, including 
also patients older than 60 years old. The first MD 
Anderson RIC allogeneic SCT study in indolent 
B-cell lymphomas showed that a conditioning 
regimen containing fludarabine and 
cyclophosphamide could provide stable 
engraftment of donor cells with a low TRM rate.
79
 
This study showed a 2-years OS of 80% that was 
impressive considering that the patients were 
highly pre-treated and refractory. A recent update 
of this study confirmed this excellent outcome 
with an estimated EFS and OS of 83% and 85%, 
respectively, after a median follow-up of 60 
months.
80
 Subsequently, other studies confirmed 
RIC efficacy and feasibility in relapsed/refractory 
FL patients, suggesting the existence of a strong 
immune-mediated antitumor activity  
(Table 3).
81-92
 Indeed, the GVL effect emerged to 
be superior in patients affected by FL compared to 
those affected by other lymphomas such as 
DLBCL.
81
 As a matter of fact, FL represents the 
only hematological disorders where alloSCT is not 
contraindicated in case of active disease before 
transplant. Indeed, several studies show that 
alloSCT can achieve long-term remissions and a 
potential disease eradication in approximately 40-
50% of FL patients with refractory and active 
disease before transplant.
93
 This high alloSCT 
immune activity was further confirmed by the
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Table 3. A summary of outcomes of allo-SCT for relapsed or refractory FL underwent alloSCT.  
Reference n°pts Conditioning regimen TRM EFS/PFS OS REF 
Khouri, et al. 2001# 20 Flu/Cy - Flu/Cy/Ritux 10% at 2 year 84%  at 2 year 84% at 2 year 79 
Robinson et al.  2002 52 Fludarabine-based 22% 61%  at 1 year 73%  at 1 year 90 
Morris et al. 2004% 41 Flu/Mel/Campath-1H 11% at 3 year 65% at 3 year 55% at 3 year 86 
Faulkner et al. 2004& 28 BEAM/Campath-1H 13.3% 69% at 2 year 63.1% at 3 year 84 
Corradini et al, 2007* 27 Flu/Cy/Thiotepa 14% at 3 year* 86%at 3 year 88% at 3 year 81 
Khouri et al, 2008 47 Flu/Cy/Ritux 15% at 5 year 85% at 5 year 83% at 5 year 80 
Hari et al, 2008 88 RIC 27% at 3 year 55% at 3 year 62% at 3 year 85 
Hari et al, 2008 120 MAC 25% at 3 year 67% at 3 year 71% at 3 year 85 
Thomson et al, 2010 82 Flu/Mel/Alemtuzumab 15% at 4 year 74% at 4 year 76% at 4 year 92 
Pinana et al. 2010 37 Flu/Mel 41% at 4 year 57% at 4 year 54% at 4 year 87 
Delgado et al. 2011 164 RIC 17% at 3 year 58% at 5 year 72% at 5 year 82 
Robinson et al. 2013 149 RIC 22% at 3 year 57% at 5 year 67% at 5 year 89 
Evens et al. 2013 48 RIC 24% at 3 year 52% at 3 year 61% at 3 year 83 
Klyuchnikov et al. 2015 268 RIC 26% at 5 year 58% at 5 year 66% at 5 year 41 
Klyuchnikov et al, 2016 61 RIC 27% at 5 year 51% at 5 year 54% at 5 year 42 
Robinson 2016+ 183 RIC 27% at 2 years 48% at 5 year 51% at 5 year 95 
#Also Small Lymphocytic Lymphoma included, %29/41 of indolent lymphoma group were FL, *including also other indolent lymphomas, 
&including also other indolent lymphoma, +All patients relapsed after ASCT. 
 
additional evidence of clinical and molecular 
responses after the withdrawal of 
immunosuppressive therapy or donor lymphocyte 
infusions.
80
 
A recent multicentre retrospective study 
included 183 relapsed/refractory after ASCT FL 
patients who received alloSCT RIC.
88
 The 5-year 
PFS and OS were 47.7% and 51.1%, respectively, 
with an acute GVHD cumulative incidence of 45% 
at 100 days and a 2-year chronic GVHD 
cumulative incidence of 51.2%. After a median 
follow-up of 58.8 months (range 3-159), the 
overall TRM was 24%. Overall, these data 
confirmed the efficacy of alloSCT among post 
ASCT relapsed FL patients and, it underlined that 
TRM and GVHD remain a big issue that affects 
approximately a quarter of all FL receiving a RIC 
alloSCT.  
Over the years, the TRM incidence decreased 
thanks to a better understanding of the GVHD and 
a more accurate diagnosis and management of 
infectious complications. In particular, the T-cell 
depletion has been shown to decrease GVHD-
related toxicity and mortality, without affecting 
the relapse risk after transplant.
17
 Unfortunately, 
despite the introduction of these new transplant 
strategies, acute and chronic GVHD still represent 
an important issue and thus novel integrated drugs 
are currently being explored in alloSCT setting. 
MD Anderson Cancer Centre showed an 
interesting and favorable outcome of the inclusion 
of anti-CD20 monoclonal antibody before and 
after transplant.
80,94
 Other clinical trials are 
currently investigating how rituximab and novel 
monoclonal antibodies may improve the 
immunosuppression without affecting the GVL 
activity. 
Historically, a good HLA-identical donor 
(sibling or unrelated) is available only for 50-60% 
of patients, thus representing one of the main 
alloSCT limitations. Recently, novel transplant 
approaches have been developed to use an 
alternative donor in lymphoma patients. 
Haploidentical donors have been used for many 
years, mostly after extensive T-cell depletion of 
peripheral stem cells, to avoid the risk of GVHD. 
However, this kind of regimen was affected by an 
unacceptable infectious toxicity and a low 
feasibility that significantly limited their extensive 
use in the clinical practice.
95
 Recently, the 
introduction of T cell-repleted haploidentical 
transplant using post-transplant cyclophosphamide 
has shown an interesting combination of low 
toxicity and low GVHD incidence compared to the 
historical haploidentical T-depleted SCT.
95-101
 
Furthermore, a large retrospective study recently 
suggested that there were no significant 
differences regarding GVHD incidence and toxic 
events between haploidentical T-cell repleted SCT 
and HLA-matched unrelated donors.
102
 This new 
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approach may guarantee the availability of a 
potential donor for all FL patients, extending the 
proportion of refractory and relapsed FL patients 
potentially eligible to alloSCT. 
As well as in ASCT setting, significant efforts 
were performed in order to improve the anti-
lymphoma activity of conditioning regimens 
without affecting neither the immunosuppression 
nor the GVL process. Excluding the previously 
cited rituximab-based RIC regimens, two main 
drugs have been successfully included in 
conditioning regimens: bendamustine and 
Zevalin®. Bendamustine combines the alkylating 
activity of the mustard group with the 
antimetabolite activity of the analog purine 
structure, and for this reason, it provides both a 
potential antitumor and immunosuppression 
activity. Considering these peculiar characteristics, 
MD Anderson tested a new RIC bendamustine-
based for indolent lymphomas. The results are 
impressive, with 2-year OS and PFS rate of 90% 
and 75%, respectively, after a median follow-up of 
26 months (range, 6-50 months).
103
 Interestingly, 
the incidence of acute grade II-IV GVHD was 
11%, and the 2-year rate of extensive chronic 
GVHD was 26%. Ongoing different clinical trials 
are exploring novel bendamustine alloSCT 
conditioning regimens to evaluate the major 
potential benefit and low toxicity effect compared 
to the historical fludarabine-based regimens. 
Zevalin®, as mentioned before, represents a well-
known active therapy in relapsed FL. Similarly to 
ASCT, some groups investigated the role of radio-
immunotherapy into the alloSCT conditioning 
regimens.
94
 An interesting combination of (90)Y-
ibritumomab tiuxetan (0.4 mCi/kg) and one of the 
most used fludarabine-based RIC regimens, 
((90)YFC) showed a cumulative incidence of 
grade II-IV acute GVHD at 100 days of 17% 
(±11%) and chronic GVHD at 12 months of 63% 
(±19%). The 2-year non-relapse mortality was 
18% (±12%), and 2-year OS, and PFS were 83% 
(±11%) and 74% (±13%), respectively. Although 
this novel conditioning regimen looks promising, 
It still needs to be established whether inclusion of 
radioimmunotherapy in the alloSCT program can 
significantly improve the final post alloSCT 
outcome. 
The FL biology knowledge is constantly 
improving, and novel pathogenetic mechanisms 
and biological subgroups have been described 
thanks to innovative genomic approaches.
38
 In the 
next future, this improvement will provide new 
potential therapeutic targets and may help discover 
distinct molecular features possibly associated 
with poorer or better outcome after alloSCT. For 
example, the recent study of Kotsiou E. et al. 
represents an early and very interesting example of 
this. Authors reported a favorable post alloSCT 
outcome associated with TNFRSF14 aberrations 
that affect 40% of all FL patients.
104
 This is the 
first demonstration of how a specific tumor 
genetic lesion may affect the capacity of tumor 
cells to stimulate allogeneic T-cell immune 
responses, generating wider consequences for 
adoptive immunotherapy strategies. 
Considering all these data, in our current 
clinical practice we candidate all eligible FL 
patients who relapse after ASCT to alloSCT 
(Figure 2). 
 
Transplant: is Always an Age Issue? Overall, 
alloSCT and ASCT anti-lymphoma efficacy are 
well established among young/fit relapsed FL 
patients. The OS and PFS results after these 
approaches have never been reached by any novel 
new drugs. Nevertheless, the long-term outcome 
of transplanted patients may be affected by late 
toxic events, especially in the alloSCT setting. In 
this scenario, a correct and multidisciplinary 
evaluation of the performance status and 
comorbidities of all relapsed FL patients should 
always be provided before the transplant, as well 
as a careful long-term follow-up after SCT. During 
the last years, several studies have highlighted that 
the sole age is not enough to exclude patients from 
more intense salvage approaches such as BMT. 
Different comorbidity scores have been proposed 
to stratify the risk of toxic and adverse events 
related to high-dose chemotherapy regimens.
105-110
 
Overall, these scores showed how relapsed FL 
patients older than 65 years but with a low number 
of comorbidities may have a significant benefit 
from intensive chemotherapy regimens without an 
excess of toxicity. This is possibly due to RIC 
regimens, better supportive care and less toxic pre-
transplant treatments both in ASCT and in 
alloSCT setting. The most used score in the 
alloSCT setting is represented by the 
hematopoietic cell transplantation comorbidity 
score (HCT-CI).
106
 This score is able to predict the 
TRM of patients undergoing an alloSCT, 
regardless of disease status. Recently, the HCT-CI 
was updated including age through different
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Figure 2. Follicular Lymphoma Relapsed after ASCT. 
 
parameters.
109
 The age threshold was 40 years old, 
confirming that among the over 40 years old 
patients, age was not sufficient to assess and 
stratify the risk of toxicity. Having more than half 
of FL patients older than 60 years old, this score 
should be applied in all the patients undergoing an 
alloSCT. 
The importance of patient comorbidity status 
straightened the role of timing in transplant 
decision-making. The transplant has not to be 
considered as a “magic wand” able to eradicate 
lymphoma cells in every time and every condition. 
The transplant outcome depends on many factors: 
delaying alloSCT or ASCT to subsequent relapses 
exposes patients to other salvage therapies, other 
potential comorbidities, as well as problems in 
donor availability. In conclusion, if we have an 
advanced early relapsed FL patient with a low 
comorbidity index, ASCT should not be delayed 
and alloSCT should be performed as soon as the 
patient achieves the best response after ASCT 
relapse. 
 
Conclusion. The continuous introduction of novel 
and effective therapies is rapidly changing the 
traditional approaches to different hematological 
cancers. As well as other lymphoproliferative 
disease, also FL is strongly involved by these 
advancements. The incorporation of novel agents 
in the anti-lymphoma therapy will hopefully 
improve our current approach to relapsed FL 
patients, and eventually partially overcome the 
actual BMT indications.
37
 Nevertheless, until now, 
no novel drugs or combinations have shown a 
superior or non-inferior clinical outcome 
compared to the results of ASCT and alloSCT in 
relapsed/refractory FL patients. Unfortunately, 
transplant-based therapies are still affected by 
significant toxicities and for this reason, a 
carefully and multidisciplinary evaluation should 
always be provided to select eligible relapsed FL 
patients rightly. 
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